列纳利多米德阻止细胞循环并调节黑色素瘤细胞中PD1-依赖的下游mTOR细胞内信号
Claudia Felici1, Anna Passarelli2, Paola Cafforio1
1Department of Internal Medicine and Clinical Oncology (DIMO), University of Bari 'Aldo Moro', Bari.
Melanoma research
|July 14, 2023
概括
列纳利多米德在黑色素瘤细胞中表现出抗增殖作用,通过阻止细胞周期进展和降低编程细胞死亡-1 (PD-1) 表达的调节. 这些发现表明lenalidomide.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚期黑色素瘤治疗反应往往是异质的和短暂的.
- 列纳利多米德是一种免疫调节剂,表现出抗癌性质,但缺乏广泛的黑色素瘤临床前数据.
- 调查lenalidomide在黑色素瘤中的疗效对于开发新型治疗策略至关重要.
研究的目的:
- 为了研究lenalidomide在黑色素瘤中的体外抗增殖活性.
- 阐明莱纳利多米德对黑色素瘤细胞影响的分子机制.
- 探索lenalidomide作为治疗晚期黑色素瘤的治疗剂的潜力.
主要方法:
- 使用MTT测定,细胞周期和细胞亡测定来评估抗增殖活性.
- 滴滴数字PCR (ddPCR) 和西部斑点分析了p21蛋白水平和CDK相互作用.
- 研究了编程细胞死亡-1 (PD-1) 调节机制,使用ddPCR,流细胞测量,西斑和siRNA转染.
主要成果:
- 列纳利多米德通过通过p21上调和CDK复合物调节在G0-G1阶段阻止细胞周期,诱导细胞静止作用.
- 列纳利多米德通过降低黑色素瘤PD-1表达的调节来表现出抗增殖作用.
- 细胞内信号通路,包括哺乳动物的拉巴素/S6的标,被莱纳利多米德治疗改变.
结论:
- 列纳利多米德在黑色素瘤细胞系上表现出显著的抗增殖和细胞静止作用.
- 该药物调节细胞周期进展和PD-1表达,提供潜在的治疗途径.
- 这些发现支持lenalidomide和类似的免疫调节剂用于瘤治疗的临床转化,针对PD-1/PD-L1轴.
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:23Negative Regulator Molecules
35.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.5K